Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Oh J, Barve M, Matthews CM, Koon EC, Heffernan TP, Fine B, Grosen E, Bergman MK, Fleming EL, DeMars LR, West L, Spitz DL, Goodman H, Hancock KC, Wallraven G, Kumar P, Bognar E, Manning L, Pappen BO, Adams N, Senzer N, Nemunaitis J. Oh J, et al. Among authors: senzer n. Gynecol Oncol. 2016 Dec;143(3):504-510. doi: 10.1016/j.ygyno.2016.09.018. Epub 2016 Sep 24. Gynecol Oncol. 2016. PMID: 27678295 Clinical Trial.
Virus-mediated killing of cells that lack p53 activity.
Nemunaitis J, Senzer N, Cunningham C, Dubensky TW. Nemunaitis J, et al. Among authors: senzer n. Drug Resist Updat. 2001 Oct;4(5):289-91. doi: 10.1054/drup.2001.0220. Drug Resist Updat. 2001. PMID: 11991681 Review. No abstract available.
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.
Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. Senzer N, et al. J Clin Oncol. 2004 Feb 15;22(4):592-601. doi: 10.1200/JCO.2004.01.227. Epub 2004 Jan 15. J Clin Oncol. 2004. PMID: 14726502 Clinical Trial.
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study.
Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, Hood J, Coffee K, Nemunaitis J. Cunningham CC, et al. Among authors: senzer n. Mol Ther. 2005 Jan;11(1):149-59. doi: 10.1016/j.ymthe.2004.09.019. Mol Ther. 2005. PMID: 15585416 Free article. Clinical Trial.
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients.
Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada S. Tong AW, et al. Among authors: senzer n. Mol Ther. 2005 Jan;11(1):160-72. doi: 10.1016/j.ymthe.2004.09.021. Mol Ther. 2005. PMID: 15585417 Free article. Clinical Trial.
120 results